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Mitochondrial-mediated oxidative stress and apoptosis play a crucial role in neurodegenerative disease and aging. Both
mitochondrial permeability transition (PT) and swelling of mitochondria have been involved in neurodegeneration. Indeed,
knockout mice for cyclophilin-D (Cyc-D), a key regulatory component of the PT pore (PTP) that triggers mitochondrial swelling,
resulted to be protected in preclinical models of multiple sclerosis (MS), Parkinson’s disease (PD), and amyotrophic lateral sclerosis
(ALS). However, how neuronal stress is transduced into mitochondrial oxidative stress and swelling is unclear. Recently, the
aging determinant p66Shc that generates H
2
O
2
reacting with cytochrome c and induces oxidation of PTP and mitochondrial
swelling was found to be involved in MS and ALS. To investigate the role of p66Shc/PTP pathway in neurodegeneration, we
performed experimental autoimmune encephalomyelitis (EAE) experiments in p66Shc knockout mice (p66Shc−/−), knock out
mice for cyclophilin-D (Cyc-D−/−), and p66Shc Cyc-D double knock out (p66Shc/Cyc-D−/−) mice. Results confirm that deletion
of p66Shc protects from EAE without affecting immune response, whereas it is not epistatic to the Cyc-Dmutation.These findings
demonstrate that p66Shc contributes to EAE induced neuronal damage most likely through the opening of PTP suggesting that
p66Shc/PTP pathway transduces neurodegenerative stresses.
1. Introduction
The p66Shc protein is the largest isoform encoded by the
ShcA locus located in the chromosome 1 in the human
or chromosome 3 in the mouse genome. The ShcA locus
encodes three isoforms through two different promoters,
one for the p46 and p52 isoforms and the other one for
the p66 isoform. Notably, the p66Shc isoform is peculiar of
vertebrates being conserved in Fucu, Xenophus, Rattus,Mus,
and Homo but not in Saccharomyces, Caenorhabditis, and
Drosophila [1]. The p52Shc and p46Shc function as adaptor
protein in signal transduction pathways linking different
activated receptor tyrosine kinases to the Ras pathway.
P66Shc is not involved in Ras activation, although p66Shc
has the typical domain organization of all members of the
Shc family of adaptor proteins. Instead, p66Shc functions in
the intracellular pathways that convert oxidative signals into
apoptosis [2, 3].
A fraction of p66Shc has been observed within the mito-
chondrial intermembrane space [4], and in vitro experiments
revealed that the recombinant p66Shc human protein inter-
acts and oxidizes Fe2+ cytochrome c to form H
2
O
2
through a
redox center that has been mapped to the N-terminus of the
p66Shc protein and ismissing in the other two ShcA isoforms
[5]. Thus, mitochondrial p66Shc sequesters electrons from
the respiratory chain to generate reactive oxygen species
(ROS).
P66Shc function is tightly regulated at multiple levels.
First of all the total amount of p66Shc is regulated by
transcriptional [6] and posttranslational mechanisms. In
particular, the half-life of p66Shc has been demonstrated
to increase upon apoptotic stimulation, notably in a p53-
dependent manner [7]. The localization of p66Shc into
mitochondrial intermembrane space is regulated by p66Shc
posttranslational modifications including serine phosphory-
lation by stress kinases like Jnk-1 and Pkc-B and prolyl-
isomerization by Pin-1, that induce p66Shc translocation
within mitochondria [8].
A further level of activation of p66Shc mitochondrial
function is represented by the availability of unbound
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p66Shc within mitochondrial vesicles. In fact, mitochon-
drial p66Shc has been observed to associate with a high
molecular weight complex of about 670KDa and to the
mitochondrial chaperon mtHsp70. Notably, treatment of
cells with proapoptotic stimuli such as Ultraviolet radi-
ation or H
2
O
2
induces the dissociation of this complex
and thus the release of monomeric p66Shc free to react
with cytochrome c [9]. Finally, the oxidation of cysteine
residues and oligomerization state of p66Shc have been
reported to regulate its redox function within mitochondria
[10].
The activation of p66Shc, and the consequentH
2
O
2
accu-
mulation in the mitochondria, impacts on the integrity of
mitochondrial inner membrane and transmembrane poten-
tial [9]. The addition of recombinant p66Shc protein to
isolated mouse liver mitochondria is sufficient to induce
opening of the PTP and ballooning of the vesicles [5]. The
key event leading to the mitochondrial swelling is indeed the
opening of the permeability transition pore (PTP), a high-
conductance inner membrane channel whose molecular
components have not been identified, that triggers the inner
membrane permeability to solutes and as consequence to
water [11].
These events are central node of cell death. During
apoptosis mitochondria undergo structural and functional
remodeling leading to the swelling of the organelles with
the subsequent release of apoptogenic factors including
cytochrome c, Smac/DIABLO, AIF, and Omi/HtrA2 into
the cytosol. These factors activate a cascade of proteases
responsible for nuclear DNA fragmentation and finally cell
death [12].The PTP open-closed state is regulated bymultiple
effectors that act on various sites [13]. In particular, it
has been shown that reactive oxygen species producing by
mitochondrial respiration are key regulators of PTP opening
[14].
Consistently with the role proposed for oxidative stress
on cell death and aging [15], primary mouse embryonic
fibroblasts (MEFs) derived from p66Shc−/− embryos have
lower intracellular concentration of ROS, as revealed by
the reduced oxidation of ROS-sensitive probes and the
reduced accumulation of endogenous markers of oxidative
stress (8-oxo-guanosine) [7]. Likewise, p66Shc−/− mice
have diminished levels of both systemic isoprostane [16]
and intracellular (nitrotyrosines, 8-oxo-guanosine) oxidative
stress [7].
Moreover, p66Shc−/− cells were shown to be resistant to
apoptosis induced by a variety of different signals, including
H
2
O
2
, UV, staurosporine, taxol, growth factor deprivation,
calcium ionophore, osmotic shock, and CD3-CD4 crosslink-
ing [2], and similarly different tissues of the p66Shc−/−
mice were found to be resistant to apoptosis induced by
paraquat [17], hypercholesterolemia [16], hyperglycemia [18],
immunotoxicity [19], and ischemia [20].
Finally it is not surprising that p66Shc−/− mice resulted
to be protected from aging-associated diseases, such as
metabolic syndrome [20, 21] atherosclerosis [16], diabetes
[18], and neurodegeneration [19, 22, 23] and show prolonged
life span [17, 21, 22], and p66Shc/PTP pathway appears a cru-
cial pathway of stress response involved in tissue dysfunction.
2. Materials and Methods
2.1. Cells. NG108-15, N2A, and the SH-SY5Y were grown
at 37∘C in 5% CO
2
in Dulbecco’s modified Eagle’s medium
(DMEM) the NG108-15, Modified Eagle’s medium (MEM)
the N2A, and the SH-SY5Y with F12 1 : 1 and 1% NeAA,
supplemented with 10% (or 15% the SH-SY5Y) fetal bovine
serum S.A. (Invitrogen, Carlsbad, CA, USA) and penicillin-
streptomycin and glutamine (100 units/mL, 100 𝜇g/mL)
(Invitrogen).
Kelly and PC12 were cultured in RPMI 1640 medium
(Gibco-BRL, Eggenstein, Germany) supplemented with 10%
FBS (and 5% Horse serum the PC12) and penicillin-
streptomycin (100 units/mL, 100 𝜇g/mL) (Invitrogen), under
5% CO
2
at 37∘C.
2.2. Western Blotting. Cells were washed twice with ice-
cold PBS and lysed with 200𝜇L of lysis buffer. Lysates were
vortexed and incubated on ice for 15min twice and then
cleared by spinning at 13.000 rpm for 5min at 4∘C. Proteins
were separated by 10% SDS—PAGE gels and immunoblotted
according to standard western blotting procedures using
primary antibody (polyclonal anti-shc, BD Biosciences).
2.3. Mice. P66Shc−/−, Cyc-D−/−, and p66Shc/Cyc-D−/−
mice were bred in the certified IFOM-IEO campus animal
facility in accordance with national and institutional guide-
lines.
Mice were housed in an air-conditioned room (temper-
ature 21 ± 1∘C, relative humidity 60 ± 10%) with a white-
red light cycle (lights on from 07:00 to 19:00) and with ad
libitum food availability (2018S Teklad Global 18% Protein
Rodent Diet, provided by Harlan Teklad) and drinking water
(autoclaved tap water).
All the in vivo experiments were performed in accordance
with Italian laws and regulations.
2.4. EAE. EAE was induced in p66Shc−/−, Cyc-D−/−,
p66Shc/Cyc-D−/−, and C57BL/6 (Wilde type, WT) female
mice (6–8 weeks of age). WT mice were obtained from
Charles River (Calco, Italy) and housed in specific pathogen-
free conditions, allowing access to food and water ad libitum.
Procedures involving animals and their care were conducted
in conformity with the institutional guidelines in compliance
with national (D.L. n. 116, G.U., suppl. 40, February 18, 1992)
and international laws and policies (EU Council Directive
86/609, OJ L 358, 1, December 12, 1987; Guide for the Care
and Use of Laboratory Animals, U.S. National Research
Council, 1996). The protocols for the proposed investigation
were reviewed and approved by the Animal of the European
Institute of Oncology. EAE was induced by subcutaneous
immunization in the flanks with a total of 200Ag ofMOG35–
55 (Multiple Peptide Systems, San Diego, CA, USA) in
incomplete Freund’s adjuvant (Sigma, St. Louis, MO, USA)
supplemented with 8mg/mL of Mycobacterium tuberculosis
(strain H37RA; Difco, Detroit, MI, USA).
Mice received 500 ng of pertussin toxin (Sigma) i.v. at
the time of immunization and 48 h later. Weight and clinical
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Figure 1: (a) P66Shc expression in different cell lines and spinal cord tissue. Western blot analysis of p66Shc was performed on whole-
cell extracts from primary mouse embryonic fibroblasts (MEF), NG108, Kelly (human neuroblastoma), N2A (mouse), PC12(rat), SH-SY5Y
(human neuroblastoma), NIH cells lines, and protein extract from mouse spinal cord. (b) Expression of p66Shc (upper panel) after UV
treatment and (lower panel) levels of PhopsorylatedSer36-p66Shc in Kelly cells. (c) Expression of p66Shc upon specific p66Shc RNAi
Interference on Kelly and response 20 𝜇MH
2
O
2
and 0.1mM Staurosporine.
score were recorded daily (0 = healthy, 1 = flaccid tail, 2 =
ataxia, and/or hind-limbs paresis, or slow righting reflex,
3 = paralysis of hind limb and/or paresis of forelimbs, 4 =
paraparesis of fore limb, and 5 = moribund or death). The
food pellets and the drinking water were placed on Petri
plates on the floor of the cage to enable sick mice to eat and
drink.
2.5. ELISA. Anti-MOG
35−55
antibody titers were examined
in the sera of the same animal groups as described previously
at day 10 after immunization. Blood from these animals was
obtained by heart puncture. Sera were collected and applied
to MOG
35−55
-coated maxisorb 96-well ELISA plates (Nalge
Nunc International, Rochester, NY) in serial dilutions. The
plates were incubated for 1 h at room temperature andwashed
four times, and 60𝜇L of 1 : 2500 diluted [HRP] 𝛼-mouse
(Amersham) peroxidase conjugated mouse anti-IgG were
applied to the wells. The plates were incubated for 40min
at room temperature and washed three times, and 60𝜇L
of ABTS + H
2
O
2
substrate were applied to the wells. The
reaction was performed at room temperature for 30min in
the dark. The level of reaction product was assessed as optic
density (OD) at 415 nm on a standard plate reader, and the
data were presented asmean SD. ODwith 𝑛 = 3 independent
measurements per group.
IL-6, IFN-𝛾, and TNF-𝛼 were measured in supernatants
of splenocytes (see the following) by ELISA (R&D Systems,
Inc., Minneapolis, MN, USA) according to the manufactur-
ers’ instructions.
2.6. Proliferation Assay. Cells from spleens of p66Shc−/− and
WT mice, stimulated or not with MOG, were cocultured for
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Figure 2: (a) ELISA assay for anti-MOG35–55 antibodies. (b) Proliferation assay. Cells from spleens, stimulated with MOG, were cocultured
for 48 h and were radiolabelled with 9,25 kBq well-1 of methyl-3H thymidine in the last 16 h of coculture. The cells are harvested and counted
in a liquid scintillation counter. (c) Cytokines production inmedium of splenocytes fromWT and p66Shc−/−mice. Results are representative
of one of two experiments, each with five mice per group.
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Figure 3: (a) EAE disease signs scores (nonparametric scale) in WT (C57BL/6) and P66Shc−/−mice have a less severe EAE disease course
than WT mice. (b) EAE disease signs scores (nonparametric scale) in WT (C57BL/6) and Cyc-D−/− mice. (c) EAE disease signs scores
(nonparametric scale) in WT (C57BL/6) and p66Shc/Cyc-D−/−mice.
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48 h and were radiolabelled with 9,25 kBq/well of methyl-3H
thymidine in the last 16 h of coculture.The cells are harvested
and counted by a beta radiation liquid scintillation counter.
3. Results and Discussion
3.1. P66Shc Determines Neuronal Cells Apoptosis. P66Shc
expression has been already demonstrated in neuronal cell
lines fromdifferentmammals [23].We confirmed byWestern
Blot (WB) analysis the expression of p66Shc in several
neuronal cell lines, in particular Kelly and SH-NY of human
origin, and in the mouse spinal cord (Figure 1(a)). The
phosphorylation of p66Shc at Serine 36 is the event activating
the proapoptotic function of p66Shc [8, 16]. WB analysis
revealed p66Shc Ser36 phosphorylation in neuronal cell lines
upon different challenges (Figure 1(b), [8]). Then, knocking
down the p66Shc expression has been found to increase
survival in Kelly cells (Figure 1(c)) as well as in other neuronal
cells [2, 23] upon oxidative stress and other pro-apoptotic
challenges. In agreement, the overexpression of p66Shc but
not of the p66ShcSer36Ala mutant increased cell death in
neuronal cells [23].
All these findings indicate that p66shc is present in
neuronal cells, including human ones and confers sensitivity
to apoptosis.
3.2. P66Shc Does Not Affect Immune Response in EAE. EAE
is an acute or chronic-relapsing, demyelinating autoimmune
disease model that closely resembles the human MS [24].
During EAE, as a consequence of specific myelin anti-
gen experimental autoimmunization, activated T- and B-
lymphocytes infiltrate the central nervous system (CNS)
where they produce large amounts of cytokines that together
with activated microglia lead to demyelination and axonal
degeneration [25, 26]. Several evidences indicate that oligo-
dendrocytes, the myelin-forming glial cells in the CNS, are
sensitive to cell death stimuli such as cytotoxic cytokines,
antimyelin antibodies, nitric oxide, and oxidative stress.
Indeed, apoptosis has been established in glial cells of both
human MS patients and EAE animal models, and it has
been proposed to be the crucial mechanism of MS and EAE
associated dysfunctions [27, 28].
To determine the role of p66Shc in EAE we compared the
results of EAE in p66Shc−/− and WT mice. First, we immu-
nized a total number of 9 isogenic WT and 9 p66Shc−/−
C57BL/6 mice with myelin oligodendrocyte glycoprotein
(MOG) 35–55 peptide following standard protocols [29, 30].
At days 8, 10, and 36 uponMOG immunization, we sacrificed
the mice (3 at each time) and extracted the blood and spleens
to investigate anti-MOG antibodies titer and MOG-induced
splenocyte proliferation, respectively. ELISA test using MOG
coated wells revealed that the concentration of antibodies
against MOG raised at the same time and extent in both
WT and p66Shc−/−mice (Figure 2(a)). Likewise, thymidine
incorporation as measure of splenocytes proliferation upon
in vitro stimulation withMOG resulted to be not significantly
altered by the deletion of p66Shc (Figure 2(b)). The secretion
of TNF-alpha, IL-6, and interferon gamma by WT and
p66Shc−/− splenocytes was comparable as well in vitro
(Figure 2(c)).
Therefore, p66Shc did not appear to influence humoral
and cellular immune response to MOG immunization.
3.3. P66Shc Deletion Delays EAE . Then we performed EAE
in WT and p66Shc−/− age matched female mice. Clinical
score and weight were recorded daily using a nonparametric
scale. Starting from 10 days (approximately depending on the
different experiments) after MOG immunization, WT mice
developed clinical symptoms, manifested as limb weakness
and paralysis (WT score at day 10, 1,80 ± 0,3, see Figure 3(a))
while p66Shc−/− mice did not (p66Shc−/− score at day 10,
0,0 see Figure 3(a)). The onset of the disease in p66Shc−/−
mice was significantly delayed (Figure 3(a) and Table 1). All
over the experiment, the p66Shc−/− showedmilder paralysis
thanWT and consistently a lower disease severity score than
WT mice (Figure 3(a)).
Notably, the 20% EAE WT mice died, whereas no
p66Shc−/− died. P66Shc deletion was found to protect
significantly from body weight loss as well (day 20 body
weight of p66Shc−/− 19,20 ± 1,36 versus WT 16,85 ± 1,13).
3.4. Cyclophilin-DDeletionDidNot Change EAEExpression in
p66Shc−/−Mice. To determine whether the protective effect
of p66Shc deletion was mediated by PTP, we investigated
the genetic interaction between the mutations of p66Shc
and of Cyc-D that increases the opening threshold of PTP
and was found to ameliorate EAE as well (Figure 3(b), [31]).
Indeed, the exact molecular composition of the PTP is
still debated [11]. However, some putative components have
been indicated, such as the voltage-dependent anion channel
(VDAC) located on the outer-mitochondrial membrane, the
adenine nucleotide translocase (ANT, located on the inner
mitochondrial membrane), and a matrix protein, Cyc-D, but
results from knockout mice of these proteins confirmed only
for Cyc-D a role in mitochondrial PT, although Cyc-D−/−
animals develop normally and undergo apoptosis in response
to certain insults [32], suggesting that additional proteins are
probably involved.
So, we generated p66Shc/Cyc-D−/− mice by crossing
p66Shc−/− and Cyc-D−/− mice both in C57BL/6 back-
ground. Then, we performed EAE on the p66Shc/Cyc-D−/−
mice, and we evaluated the evolution of their disease over a
month. The onset and development of EAE in p66Shc/Cyc-
D−/− mice resulted to be identical to those observed for
p66Shc−/−mice (Figure 3(c) and Table 2). Notably, the early
onset of disease typical of Cyc-D null mice (Figure 3(b),
[31]) was lost when also p66Shc was mutated suggesting that
p66Shc is necessary for the expression of disease before time
by the Cyc-D mutation.
These results indicate that the deletion Cyc-D was not
epistatic to the deletion of p66Shc with respect to the to EAE
protection.
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Table 1: Clinical EAE parameters in WT and p66Shc−/−mice.
Strain Disease onset (day 10) score Disease onset (day 13) score Number of mice with score ≥3 Mean maximum score AUC (days)
WT 1.80 ± 0.3 2.20 ± 0.34 3/5 3.20 ± 0.50 21.95 ± 3.54
P66Shc−/− 0 1.00 ± 0.43 2/5 2.5 ± 0.62 13.65 ± 4.91
Data are mean of three independent experiments ± SE. (AUC: area under the curve) values are calculated at day 20 from the immunization.
Table 2: Clinical EAE parameters in WT, Cyc-D−/−, and p66Shc/Cyc-D−/−mice.
Strain Disease onset(day 11) score
Disease onset
(day 13) score
Survival at
sacrifice
Day 27
Number of
mice
with score ≥3
Day of
maximal
score
Mean
maximum
score
AUC (days)
WT 0.75 ± 0.33 2.45 ± 0.18 3/10 10/10 20 4.7 ± 0.21 22.10 ± 2.91
Cyc-D−/− 0 2.08 ± 0.30 6/6 4/6 14 3.17 ± 0.31 26.83 ± 2.55
P66Shc/Cyc-D−/− 0 1.14 ± 0.37 6/7 5/7 21 3.85 ± 0.35 23.50 ± 2.24
Data are mean three independent experiments ± SE. Values are calculated at day 20 from the immunization.
4. Conclusions
Neurodegenerative disease is complex trait disorder that
involves several stress response pathways inducing mito-
chondrial apoptosis. Classical genetics studies, to identify
susceptibility genes, are more difficult than for simple
mendelian disorders because of the number of loci involved,
the incomplete penetrance, and the important role of envi-
ronmental factors.
Results form in vitro experiments showing that p66Shc
increases oxidative stress to the mitochondria and the Cyc-
D-dependent PTP particularly supported the hypothesis of
a genetic interaction of p66Shc and Cyc-D. So, to validate
the role of the p66Shc-PTP pathway in neurodegenerationwe
have studied in mice the epistasis of p66Shc and Cyc-D null
mutations on the susceptibility to EAE.
Results from these experiments revealed that both muta-
tionsmitigated the disease, but their effects were not additive.
These findings indicate that the p66Shc and Cyc-D are
epistatic and validate the hypothesis that p66Shc activation
by stresses converges to the PTPopening to inducemitochon-
drial swelling in neurons.
Therefore, early detection of p66Shc activation (expres-
sion levels, specific phosphorylation) or its inhibition may
represent valid approaches to treat neurodegeneration.
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